148 related articles for article (PubMed ID: 17786536)
1. Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone.
Sone S; Yano S
Cancer Metastasis Rev; 2007 Dec; 26(3-4):685-9. PubMed ID: 17786536
[TBL] [Abstract][Full Text] [Related]
2. Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity.
Muguruma H; Yano S; Kakiuchi S; Uehara H; Kawatani M; Osada H; Sone S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8822-8. PubMed ID: 16361571
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid hormone-related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC-5 cells in natural killer cell-depleted SCID mice.
Miki T; Yano S; Hanibuchi M; Kanematsu T; Muguruma H; Sone S
Int J Cancer; 2004 Feb; 108(4):511-5. PubMed ID: 14696114
[TBL] [Abstract][Full Text] [Related]
5. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models.
Yoneda T; Michigami T; Yi B; Williams PJ; Niewolna M; Hiraga T
Cancer Treat Rev; 1999 Oct; 25(5):293-9. PubMed ID: 10544073
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
7. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
8. Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Yamada T; Muguruma H; Yano S; Ikuta K; Ogino H; Kakiuchi S; Hanibuchi M; Uehara H; Nishioka Y; Sone S
Mol Cancer Ther; 2009 Jan; 8(1):119-26. PubMed ID: 19139120
[TBL] [Abstract][Full Text] [Related]
9. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice.
Miki T; Yano S; Hanibuchi M; Sone S
Oncol Res; 2000; 12(5):209-17. PubMed ID: 11417746
[TBL] [Abstract][Full Text] [Related]
10. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
Zhang H; Yano S; Miki T; Goto H; Kanematsu T; Muguruma H; Uehara H; Sone S
Clin Exp Metastasis; 2003; 20(2):153-9. PubMed ID: 12705636
[TBL] [Abstract][Full Text] [Related]
11. [Mechanism and treatment of cancer metastasis to bone].
Yoneda T
Clin Calcium; 2005 Jul; 15(7):29-37. PubMed ID: 15995293
[TBL] [Abstract][Full Text] [Related]
12. [The application advances of bisphosphonates in bone metastasis].
Liang P
Zhongguo Gu Shang; 2008 Jun; 21(6):480-2. PubMed ID: 19108448
[TBL] [Abstract][Full Text] [Related]
13. [Encounter of cancer cells with bone. Development of bone metastasis-specific targeting therapy].
Hayashi S; Hanamura T
Clin Calcium; 2011 Mar; 21(3):389-96. PubMed ID: 21358060
[TBL] [Abstract][Full Text] [Related]
14. Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice.
Ogino H; Yano S; Kakiuchi S; Muguruma H; Ikuta K; Hanibuchi M; Uehara H; Tsuchida K; Sugino H; Sone S
Clin Cancer Res; 2008 Feb; 14(3):660-7. PubMed ID: 18245525
[TBL] [Abstract][Full Text] [Related]
15. [Encounter of cancer cells with bone. Therapy for bone metastasis from lung cancer].
Sugiura H
Clin Calcium; 2011 Mar; 21(3):439-45. PubMed ID: 21358066
[TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinoma bone metastasis--elucidating the molecular targets.
Weber K; Doucet M; Kominsky S
Cancer Metastasis Rev; 2007 Dec; 26(3-4):691-704. PubMed ID: 17768599
[TBL] [Abstract][Full Text] [Related]
17. The critical role of bisphosphonates to target bone cancer metastasis: an overview.
Singh T; Kaur V; Kumar M; Kaur P; Murthy RS; Rawal RK
J Drug Target; 2015 Jan; 23(1):1-15. PubMed ID: 25203856
[TBL] [Abstract][Full Text] [Related]
18. On the horizon: can bisphosphonates prevent bone metastases?
Coleman R
Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
[TBL] [Abstract][Full Text] [Related]
19. [Pamidronate therapy for lung cancer patients with bone metastasis].
Oura S; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Ohta F; Naito Y
Gan To Kagaku Ryoho; 2000 Jul; 27(7):1057-60. PubMed ID: 10925695
[No Abstract] [Full Text] [Related]
20. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P
Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
